Enanta Pharmaceuticals, Inc. (ENTA) News

Enanta Pharmaceuticals, Inc. (ENTA): $43.06

-2.18 (-4.82%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ENTA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 379

in industry

Filter ENTA News Items

ENTA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ENTA News Highlights

  • ENTA's 30 day story count now stands at 7.
  • Over the past 14 days, the trend for ENTA's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about ENTA are ACT and TOP.

Latest ENTA News From Around the Web

Below are the latest news stories about ENANTA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ENTA as an investment opportunity.

Newsflash: Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Analysts Have Been Trimming Their Revenue Forecasts

Today is shaping up negative for Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) shareholders, with the analysts...

Yahoo | November 23, 2022

Enanta Pharmaceuticals to Participate in Two Investor Conferences in November

WATERTOWN, Mass., November 22, 2022--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two investor conferences being webcast in November:

Yahoo | November 22, 2022

Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Lags Revenue Estimates

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 7.30% and 9.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 21, 2022

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET

WATERTOWN, Mass., November 21, 2022--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today reported financial results for its fiscal fourth quarter and year ended September 30, 2022.

Yahoo | November 21, 2022

Enanta Pharmaceuticals to Host Conference Call on November 21 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Fourth Quarter and Full Year Ended September 30, 2022

WATERTOWN, Mass., November 14, 2022--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that it plans to report its financial results for its fiscal fourth quarter and full year ended September 30, 2022 after the U.S. market closes on November 21, 2022. Enanta management will then host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta’s busine

Yahoo | November 14, 2022

Enanta Pharmaceuticals (ENTA) Gets a Buy from JMP Securities

In a report released today, Roy Buchanan from JMP Securities reiterated a Buy rating on Enanta Pharmaceuticals (ENTA - Research Report), with a price target of $97.00. The company's shares closed today at $41.44.According to TipRanks, Buchanan is an analyst with an average return of -31.1% and a 19.35% success rate. Buchanan covers the Healthcare sector, focusing on stocks such as Arbutus Biopharma, PolyPid, and Dynavax.Enanta Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $71.60.See the top stocks recommended by analysts >>The company has a one-year high of $95.71 and a one-year low of $37.59. Currently, Enanta Pharmaceuticals has an average volume of 204.1K.

Ryan Adist on TipRanks | November 9, 2022

Enanta Pharmaceuticals Initiates SPRINT, a Phase 2 Clinical Trial of EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19

WATERTOWN, Mass., November 09, 2022--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced the initiation of SPRINT (SARS-Cov-2 PRotease INhibitor Treatment), a Phase 2 clinical trial of EDP-235, Enanta’s lead oral, 3CL protease inhibitor, in non-hospitalized, symptomatic adults with mild or moderate COVID-19. The study is designed to evaluate the safety, tolerability, and antiviral act

Yahoo | November 9, 2022

Investors in Enanta Pharmaceuticals (NASDAQ:ENTA) have unfortunately lost 51% over the last year

The nature of investing is that you win some, and you lose some. Anyone who held Enanta Pharmaceuticals, Inc...

Yahoo | November 3, 2022

Enanta Pharmaceuticals Presents New Preclinical Data for EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19 at IDWeek™ 2022

WATERTOWN, Mass., October 19, 2022--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced new preclinical data supporting the potential of EDP-235 for the treatment of COVID-19, which are being presented at IDWeek 2022 in Washington, DC.

Yahoo | October 19, 2022

Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-323, its Novel, Oral L-Protein Inhibitor in Development for the Treatment Respiratory Syncytial Virus

WATERTOWN, Mass., October 17, 2022--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it has dosed the first subject in its Phase 1 clinical trial of EDP-323, a novel, oral L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV).

Yahoo | October 17, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5781 seconds.